The New England Journal of Medicine » Rheumatoid Arthritis
12 FOLLOWERS
The New England Journal of Medicine (NEJM.org) is the world's leading medical journal and website. The Rheumatoid Arthritis category contains articles and information from the New England Journal of Medicine.
The New England Journal of Medicine » Rheumatoid Arthritis
1M ago
The management of autoimmune diseases has improved substantially since the turn of the century, owing largely to the emergence of targeted biologic therapies. Nonetheless, treatment is still considered to be disease-suppressive and lifelong in most cases. In this issue of the , Müller et al. describe a series ..read more
The New England Journal of Medicine » Rheumatoid Arthritis
1M ago
In this case series of 15 patients with severe autoimmune disease, selective deep depletion of B lymphocytes with CD19 CAR T-cell therapy was effective in achieving clinical remission ..read more
The New England Journal of Medicine » Rheumatoid Arthritis
11M ago
Programmed cell death protein 1 (PD-1) is a critical inhibitory receptor in lymphocyte activation, acting as an immune checkpoint to prevent the continued activation of T cells after an immune response and to maintain peripheral immune tolerance. PD-1 is a marker of antigen-experienced T cells. With sustained T-cell stimulation ..read more
The New England Journal of Medicine » Rheumatoid Arthritis
1y ago
A 44-year-old woman with rheumatoid arthritis was evaluated because of proximal muscle weakness and myalgia. She had difficulty raising her arms above her head. Diagnostic tests were performed ..read more
The New England Journal of Medicine » Rheumatoid Arthritis
1y ago
Rheumatoid arthritis is a chronic, systemic autoimmune disease manifested primarily as inflammatory arthritis, typically involving the small joints of the hands and feet. It can lead to severe disability and death ..read more
The New England Journal of Medicine » Rheumatoid Arthritis
1y ago
In patients with rheumatoid arthritis, the monoclonal antibody against interleukin-6, olokizumab, was superior to placebo and noninferior to adalimumab at 12 weeks ..read more
The New England Journal of Medicine » Rheumatoid Arthritis
2y ago
In this randomized noninferiority trial involving patients with rheumatoid arthritis, cardiovascular events and cancers occurred more frequently with tofacitinib than with a TNF inhibitor, and noninferiority of tofacitinib with respect to these end points was not established ..read more
The New England Journal of Medicine » Rheumatoid Arthritis
2y ago
The Food and Drug Administration (FDA) mandated a safety study to be performed because of possible safety signals detected for the Janus kinase (JAK) inhibitor tofacitinib. As Ytterberg et al. report in this issue of the , the Oral Rheumatoid Arthritis Trial (ORAL) Surveillance was a 4-year ..read more
The New England Journal of Medicine » Rheumatoid Arthritis
2y ago
In this study, a gain-of-function variant in the promoter of that was previously found to be associated with idiopathic pulmonary fibrosis was associated with rheumatoid arthritis–associated interstitial lung disease ..read more
The New England Journal of Medicine » Rheumatoid Arthritis
2y ago
A 69-year-old woman with rheumatoid arthritis presented for the treatment of severe joint deformities. Examination of the hands, shown in a video, revealed telescoping fingers ..read more